Levothyroxine Sodium
Brand names: Euthyrox, Levo-T, Levothyroxine Sodium, Ermeza, Levoxyl, Synthroid, Thyquidity, Tirosint, Tirosint-Sol, Unithroid
At a glance
- Medicare prescriptions, 2024
- 46,625,626
- Medicare drug cost
- $771.9M
- Average cost per prescription
- $16.56
- Clinicians who prescribed it
- 282,609
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Hypothyroidism SYNTHROID is indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
From the FDA-approved prescribing information (label dated February 2024). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life - threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 34.7%
- Internal Medicine 28.2%
- Nurse Practitioners 17.1%
- Endocrinology & Diabetes 6.8%
- Physician Assistants 5.8%
- General Practice 2.1%
- Geriatric Medicine 1.7%
- Cardiology 0.5%
- Hospitalist 0.4%
- Nephrology (Kidney) 0.3%
- Hematology & Oncology 0.3%
- Pulmonology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 4% from 2019 to 2024.
Biggest change by state since 2019
- District of Columbia +18%
- Utah +17%
- Maryland +16%
- Idaho +15%
- Alaska +15%
- Mississippi (smallest change) −6%
- Rhode Island (smallest change) −3%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
AbbVie Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 ug | orange round tablet, 7 mm, scored to split in 2 | SYNTHROID 25 |
| 50 ug | white round tablet, 7 mm, scored to split in 2 | SYNTHROID 50 |
| 75 ug | purple round tablet, 7 mm, scored to split in 2 | SYNTHROID 75 |
| 88 ug | green round tablet, 7 mm, scored to split in 2 | SYNTHROID 88 |
| 100 ug | yellow round tablet, 7 mm, scored to split in 2 | SYNTHROID 100 |
| 112 ug | red round tablet, 7 mm, scored to split in 2 | SYNTHROID 112 |
| 125 ug | brown round tablet, 7 mm, scored to split in 2 | SYNTHROID 125 |
| 137 ug | blue round tablet, 7 mm, scored to split in 2 | SYNTHROID 137 |
| 150 ug | blue round tablet, 7 mm, scored to split in 2 | SYNTHROID 150 |
| 175 ug | purple round tablet, 7 mm, scored to split in 2 | SYNTHROID 175 |
| 200 ug | pink round tablet, 7 mm, scored to split in 2 | SYNTHROID 200 |
| 300 ug | green round tablet, 7 mm, scored to split in 2 | SYNTHROID 300 |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 25 ug | orange capsule, 10 mm, scored to split in 2 | 25 T 4 |
Pfizer Laboratories Div Pfizer Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 25 ug | orange oval tablet, 10 mm, scored to split in 2 | LEVOXYL DP 25 |
| 50 ug | white oval tablet, 10 mm, scored to split in 2 | LEVOXYL DP 50 |
| 75 ug | purple oval tablet, 10 mm, scored to split in 2 | LEVOXYL DP 75 |
| 88 ug | green oval tablet, 10 mm, scored to split in 2 | LEVOXYL DP 88 |
| 100 ug | yellow oval tablet, 10 mm, scored to split in 2 | LEVOXYL DP 100 |
| 112 ug | pink oval tablet, 10 mm, scored to split in 2 | LEVOXYL DP 112 |
| 125 ug | brown oval tablet, 10 mm, scored to split in 2 | LEVOXYL DP 125 |
| 137 ug | blue oval tablet, 10 mm, scored to split in 2 | LEVOXYL DP 137 |
| 150 ug | blue oval tablet, 10 mm, scored to split in 2 | LEVOXYL DP 150 |
| 175 ug | turquoise oval tablet, 10 mm, scored to split in 2 | LEVOXYL DP 175 |
| 200 ug | pink oval tablet, 10 mm, scored to split in 2 | LEVOXYL DP 200 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $617,870 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- AbbVie Inc. $344,449
- Amneal Pharmaceuticals LLC $139,901
- Ibsa Pharma Inc. $131,557
- Ibsa Institut Biochimique SA $1,963
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
17 recalls since 2020
- Sep 2026 · Pfizer · Class II
Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing. - Aug 2026 · Accord Healthcare, Inc. · Class II
Subpotent Drug - Jul 2026 · Major Pharmaceuticals · Class II
Subpotent Drug - Jun 2026 · Accord Healthcare, Inc. · Class II
Subpotent Drug - Feb 2026 · Macleods Pharma USA, Inc · Class II
Subpotent Drug - Sep 2025 · Accord Healthcare, Inc. · Class II
Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range. - Jul 2025 · Pfizer · Class II
Subpotent drug - Jun 2025 · Accord Healthcare, Inc. · Class II
Subpotent Drug: Assay below the approved specification
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.